JENACELL GMBH

Their core work

JenaCell is a German biotech SME based in Jena that specializes in bacterial nanocellulose (BNC) biomaterials for medical and therapeutic applications. They contribute biomaterial expertise to EU-funded research networks focused on cancer therapy, tissue regeneration, and nanomedicine. Their role in MSCA training and mobility projects indicates they host early-stage researchers and provide an industry environment for translating cellulose-based biomaterials into clinical products. Their project portfolio spans immunotherapy delivery, RNA-based cancer therapeutics, and cartilage tissue engineering.

What they specialise in

How they've shifted over time

JenaCell's early H2020 work (2016–2018) centered on cancer immunotherapy and image-guided surgery, providing biomaterial support for postoperative treatment approaches. From 2020 onward, their focus shifted notably toward RNA-based cancer therapeutics and musculoskeletal tissue regeneration using nanomedicine and non-viral gene therapy. This evolution signals a broadening from cancer-only applications toward a wider regenerative medicine scope, with increasing emphasis on advanced delivery systems.

JenaCell is moving from cancer-focused biomaterials toward a broader nanomedicine platform spanning both oncology and musculoskeletal regeneration, suggesting readiness for diverse therapeutic delivery collaborations.

How they like to work

JenaCell operates exclusively as a participant — never as coordinator — which is typical for a specialist SME contributing specific material or technology expertise to larger academic-led consortia. With 40 unique partners across 14 countries from just 4 projects, they integrate into large MSCA networks (training and mobility schemes) where broad international reach is built into the programme design. This makes them an accessible, low-friction industry partner accustomed to working with diverse academic groups across Europe.

Despite only four projects, JenaCell has collaborated with 40 unique partners across 14 countries, a direct result of participating in large MSCA training networks. Their network is geographically broad across the EU with no strong concentration in any single region.

What sets them apart

JenaCell occupies a niche as an SME that bridges biomaterial manufacturing with academic therapeutic research through MSCA training programmes. Unlike purely academic biomaterial labs, they bring an industry perspective on manufacturability and translation to clinical use. For consortium builders, they offer a credible German SME partner with hands-on experience hosting researchers and a biomaterial platform applicable across oncology, regenerative medicine, and nanomedicine.

Highlights from their portfolio

• CARTHAGO
  Largest single EC contribution (EUR 252,788) and represents a strategic expansion into cartilage regeneration and non-viral gene therapy beyond their cancer therapy roots.
• cONCReTE
  Focused specifically on RNA cancer therapeutics — a high-growth field post-COVID — positioning JenaCell at the intersection of biomaterials and RNA medicine.
• ISPIC
  Their earliest H2020 project combining image-guided surgery with immunotherapy, establishing JenaCell's entry into EU collaborative cancer research.